Interestingly, a phase I trial investigating MK-2206 in combination with paclitaxel and carboplatin for the treatment of two patients with BRAF-wild-type stage IV melanoma reported long-term, enhanced responses to chemotherapy [NCT00848718 (Rebecca et al., 2014)]. Here, BRAF is linked to melanoma.